Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BILR 355
- Development stage
- Discontinued
- Lead developer
- Boehringer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BILR 355 is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) developed for the treatment of human immunodeficiency virus (HIV) infection. It was designed to be effective against HIV strains resistant to first-generation NNRTIs. The drug is an orally active small molecule and was investigated in combination with ritonavir to enhance its pharmacokinetic profile. Clinical studies showed that it could suppress viral growth in both wild-type and NNRTI-resistant HIV isolates. Development reached phase II clinical trials but was discontinued for HIV infections[1][3][5].
- Other names
- 6H-Dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one 11-ethyl-5,11-dihydro-5-methyl-8-[2-[(1-oxido-4-quinolinyl)oxy]ethyl]11-ethyl-5,11-dihydro-5-methyl-8-(2-(1-oxidoquinolinyl)ethyl)-6H-dipyrido(3,2-b;2',3'-e)(1,4)diazepinone
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on BILR 355.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BILR 355.